Skip to content

About Taivex
Our Products
News
- Project
- Award
Contact Us

Menu

About Taivex
Our Products
News
- Project
- Award
Contact Us

Company Profile

cropped-Taivex-favicon.png

By jeff

https://www.taivex.com/wp-content/uploads/2022/10/cropped-Taivex-favicon.png

Post navigation

← Previous Media

Search for:

Recent Posts

Enrollment of the first patient for T-1301 Phase I clinical trial was achieved in August, 2022.
T-1101 be invited for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023)
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021
NHRI Enters Technology Transfer Agreement of T-1501 (DBPR186) with Taivex Therapeutics Corp.
Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the Taiwan FDA to conduct Phase I clinical trial

Archives

August 2022
June 2022
December 2021
September 2021
August 2021
July 2021
June 2021
April 2021
January 2021
December 2020
November 2020
October 2019
April 2019
August 2018
September 2017
July 2017
January 2017
September 2016
August 2016
November 2011

Categories

Award
Project

Meta

Log in
Entries feed
Comments feed
WordPress.org

2F., No. 12, Dongxing Rd., Songshan Dist., Taipei City 105 , Taiwan (R.O.C.)
TEL：+886-2-27486200
FAX：+886-2-27486208
MAIL：mail@taivex.com

About Taivex

Profile
Milestone
Business Model
Organization

Pipeline

T-1101
T-1201
T-1301
T-1501

News

Award
Project

Taivex Therapeutics Corporation. Co., Ltd 2023 © All rights reserved. 網頁設計公司：振作國際

Scroll to Top